• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

体外膜肺氧合治疗心脏手术后心源性休克的结果:单中心经验。

Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience.

机构信息

Department of Cardiothoracic Surgery, Heart Center, University of Cologne, Cologne, Germany.

出版信息

J Surg Res. 2013 May;181(2):e47-55. doi: 10.1016/j.jss.2012.07.030. Epub 2012 Aug 1.

DOI:10.1016/j.jss.2012.07.030
PMID:22878151
Abstract

BACKGROUND

We assessed the short-term outcomes and predictors of 30-d mortality in patients requiring temporary, peripheral extracorporeal membrane oxygenation (ECMO) for postcardiotomy cardiac failure.

METHODS

The data were retrospectively obtained using our institutional patient database. All patients who had received peripheral ECMO support after surgery for acquired heart disease from 2006 to 2010 were included in the present study. The demographic and perioperative variables of the 30-d survivors and nonsurvivors were compared using the chi-square and t-test, and multivariate logistic regression analysis was performed to identify the predictors of 30-d all-cause mortality.

RESULTS

A total of 77 patients with a mean age of 60 ± 13 years were included in the present analysis. Successful weaning from peripheral ECMO was achieved in 62% after 79 ± 57 h of ECMO support. The overall 30-d mortality rate was 70%, and mortality was reduced to 52% in the patients in whom ECMO support could be weaned successfully. Age (per year) at ECMO implantation was the only independent preoperative predictor of 30-d mortality (odds ratio 1.09, 95% confidence interval 1.03-1.15; P = 0.003). In addition, greater lactate levels after 24 h of ECMO therapy, a longer duration of ECMO support, and the presence of any ECMO-related or gastrointestinal complications were independent predictive factors for 30-d mortality (P < 0.05).

CONCLUSIONS

ECMO therapy provides a valuable therapeutic strategy for postcardiotomy myocardial failure but is still limited by high complication rates with fewer than 30% of patients discharged from the hospital. Patient age appears to be an essential preoperative predictor for mortality, and the blood lactate level is a relevant marker for the assessment of efficient ECMO support.

摘要

背景

我们评估了因心脏手术后心力衰竭而需要临时外周体外膜肺氧合(ECMO)的患者在 30 天内的死亡率和短期预后。

方法

使用我们的机构患者数据库回顾性地获取数据。本研究纳入了 2006 年至 2010 年间因获得性心脏病手术后接受外周 ECMO 支持的所有患者。使用卡方检验和 t 检验比较 30 天幸存者和非幸存者的人口统计学和围手术期变量,并进行多变量逻辑回归分析以确定 30 天全因死亡率的预测因素。

结果

共纳入 77 例患者,平均年龄为 60 ± 13 岁。在接受 ECMO 支持 79 ± 57 小时后,有 62%的患者成功撤机。总的 30 天死亡率为 70%,在能够成功撤机的患者中,死亡率降至 52%。ECMO 植入时的年龄(每年)是 30 天死亡率的唯一独立术前预测因素(优势比 1.09,95%置信区间 1.03-1.15;P = 0.003)。此外,ECMO 治疗后 24 小时乳酸水平更高、ECMO 支持时间更长以及存在任何 ECMO 相关或胃肠道并发症是 30 天死亡率的独立预测因素(P < 0.05)。

结论

ECMO 治疗为心脏手术后心肌衰竭提供了有价值的治疗策略,但由于并发症发生率较高,仅有不到 30%的患者出院,仍受到限制。患者年龄似乎是死亡率的一个重要术前预测因素,而血乳酸水平是评估 ECMO 支持效果的相关标志物。

相似文献

1
Outcomes after peripheral extracorporeal membrane oxygenation therapy for postcardiotomy cardiogenic shock: a single-center experience.体外膜肺氧合治疗心脏手术后心源性休克的结果:单中心经验。
J Surg Res. 2013 May;181(2):e47-55. doi: 10.1016/j.jss.2012.07.030. Epub 2012 Aug 1.
2
Creatine kinase isoenzyme MB relative index as predictor of mortality on extracorporeal membrane oxygenation support for postcardiotomy cardiogenic shock in adult patients.肌酸激酶同工酶MB相对指数作为成人心脏术后心源性休克体外膜肺氧合支持下死亡率的预测指标
Eur J Cardiothorac Surg. 2006 Oct;30(4):617-20. doi: 10.1016/j.ejcts.2006.07.016. Epub 2006 Aug 28.
3
The early dynamic behavior of lactate is linked to mortality in postcardiotomy patients with extracorporeal membrane oxygenation support: A retrospective observational study.体外膜肺氧合支持下心内直视术后患者乳酸的早期动态变化与死亡率相关:一项回顾性观察研究。
J Thorac Cardiovasc Surg. 2015 May;149(5):1445-50. doi: 10.1016/j.jtcvs.2014.11.052. Epub 2014 Nov 24.
4
Early and intermediate results of rescue extracorporeal membrane oxygenation in adult cardiogenic shock.成人心源休克中体外膜肺氧合抢救的早期和中期结果。
Ann Thorac Surg. 2009 Dec;88(6):1897-903. doi: 10.1016/j.athoracsur.2009.08.009.
5
Extracorporeal membrane oxygenation for refractory cardiogenic shock after cardiac surgery: predictors of early mortality and outcome from 51 adult patients.体外膜肺氧合治疗心脏手术后难治性心源性休克:51 例成人患者早期死亡率和预后的预测因素。
Eur J Cardiothorac Surg. 2010 Feb;37(2):328-33. doi: 10.1016/j.ejcts.2009.07.033. Epub 2009 Sep 12.
6
Extracorporeal membrane oxygenation to support adult patients with cardiac failure: predictive factors of 30-day mortality.体外膜肺氧合支持成年心力衰竭患者:30天死亡率的预测因素
Interact Cardiovasc Thorac Surg. 2010 May;10(5):721-6. doi: 10.1510/icvts.2009.220335. Epub 2010 Feb 1.
7
[Clinical experience with adults receiving extracorporeal membrane oxygenation for cardiogenic shock and quality of life in survivals].[成人接受体外膜肺氧合治疗心源性休克的临床经验及存活者的生活质量]
Zhonghua Yi Xue Za Zhi. 2010 Feb 2;90(5):310-4.
8
Peripheral extracorporeal membrane oxygenation system as salvage treatment of patients with refractory cardiogenic shock: preliminary outcome evaluation.外周体外膜肺氧合系统作为难治性心源性休克患者的挽救性治疗:初步结果评估。
Artif Organs. 2012 Mar;36(3):E53-61. doi: 10.1111/j.1525-1594.2011.01423.x. Epub 2012 Feb 21.
9
[Extracorporeal membrane oxygenation for the treatment of refractory cardiogenic shock in adults: strategies, results, and predictors of mortality].[体外膜肺氧合治疗成人难治性心源性休克:策略、结果及死亡预测因素]
G Ital Cardiol (Rome). 2014 Oct;15(10):577-85. doi: 10.1714/1672.18312.
10
Extracorporeal membrane oxygenation support in refractory cardiogenic shock: treatment strategies and analysis of risk factors.难治性心源性休克的体外膜肺氧合支持:治疗策略及危险因素分析
Artif Organs. 2014 Jul;38(7):E129-41. doi: 10.1111/aor.12317. Epub 2014 May 20.

引用本文的文献

1
The early and mid-term outcomes of acute type A aortic dissection patients with ECMO.接受体外膜肺氧合(ECMO)治疗的急性A型主动脉夹层患者的早期和中期结果。
Front Cardiovasc Med. 2024 Dec 20;11:1509479. doi: 10.3389/fcvm.2024.1509479. eCollection 2024.
2
Optimizing Outcomes in Extracorporeal Membrane Oxygenation Postcardiotomy in Pediatric Population.优化儿科心脏术后体外膜肺氧合的治疗效果
J Pediatr Intensive Care. 2021 Jul 3;12(4):245-255. doi: 10.1055/s-0041-1731682. eCollection 2023 Dec.
3
Veno-arterial extracorporeal membrane oxygenation for post-infarction ventricular septal defect in a low-volume center.
低容量中心应用静脉-动脉体外膜肺氧合治疗心肌梗死后室间隔穿孔
J Extra Corpor Technol. 2023 Sep;55(3):144-146. doi: 10.1051/ject/2023013. Epub 2023 Sep 8.
4
Gastrointestinal haemorrhage in extracorporeal membrane oxygenation: insights from the national inpatient sample.体外膜肺氧合中的胃肠道出血:来自全国住院患者样本的见解
Arch Med Sci. 2021 Jan 26;19(3):600-607. doi: 10.5114/aoms/112199. eCollection 2023.
5
Perioperative incidence of ECMO and IABP on 5901 mitral valve surgery procedures.5901 例二尖瓣手术中 ECMO 和 IABP 的围术期发生率。
J Cardiothorac Surg. 2022 Mar 17;17(1):38. doi: 10.1186/s13019-022-01790-1.
6
Understanding the "extracorporeal membrane oxygenation gap" in veno-arterial configuration for adult patients: Timing and causes of death.了解成人患者静脉-动脉配置中的“体外膜氧合间隙”:死亡时间和原因。
Artif Organs. 2021 Oct;45(10):1155-1167. doi: 10.1111/aor.14006. Epub 2021 Jul 6.
7
Cardioprotective shock management: monitoring and supportive therapies.心脏保护休克管理:监测与支持治疗
Eur Heart J Suppl. 2021 Mar 27;23(Suppl A):A3-A9. doi: 10.1093/eurheartj/suab001. eCollection 2021 Mar.
8
Acute vascular complications of femoral veno-arterial ECMO: a single-centre retrospective study.股静脉-动脉体外膜肺氧合的急性血管并发症:一项单中心回顾性研究。
Egypt Heart J. 2021 Feb 19;73(1):15. doi: 10.1186/s43044-021-00143-y.
9
30-Day perioperative mortality following venoarterial extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock in patients with normal preoperative ejection fraction.体外膜肺氧合治疗围术期正常射血分数患者心脏手术后心源性休克 30 天死亡率。
Interact Cardiovasc Thorac Surg. 2021 May 10;32(5):817-824. doi: 10.1093/icvts/ivaa323.
10
Veno-Arterial Extracorporeal Membrane Oxygenation in the Adult: A Bridge to the State of the Art.成人静脉-动脉体外膜肺氧合:通向技术前沿的桥梁。
Curr Cardiol Rev. 2021;17(4):e290421188337. doi: 10.2174/1573403X16999201124202144.